-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, UTPrPBo2xghEPsktwrEqHreWK5wjYBit+NHEZV6mKfUHLWV56EKet8D8k7O9CXd/ JI6iiToT31t7BGQ1GH3XwA== 0001012870-98-002810.txt : 19981111 0001012870-98-002810.hdr.sgml : 19981111 ACCESSION NUMBER: 0001012870-98-002810 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 19981106 ITEM INFORMATION: ITEM INFORMATION: FILED AS OF DATE: 19981110 FILER: COMPANY DATA: COMPANY CONFORMED NAME: DEPOMED INC CENTRAL INDEX KEY: 0001005201 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731] IRS NUMBER: 943229046 STATE OF INCORPORATION: CA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: SEC FILE NUMBER: 001-13111 FILM NUMBER: 98741229 BUSINESS ADDRESS: STREET 1: 1170 B CHESS DR CITY: FOSTER CITY STATE: CA ZIP: 94404-1167 BUSINESS PHONE: 4155130990 MAIL ADDRESS: STREET 1: 1170 B CHESS DRIVE CITY: FOSTER CITY STATE: CA ZIP: 94404 8-K 1 FORM 8-K SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 ___________ FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): November 6, 1998 DEPOMED, INC. - -------------------------------------------------------------------------------- (Exact name of registrant as specified in its charter) California 001-13111 94-3229046 - ------------------------------------------------------------------------------- (State of Incorporation (Commission File Number) (I.R.S. Employer or Organization) Identification No.) 366 Lakeside Drive, Foster City, California 94404 - ------------------------------------------------------ --------------------- (Address of principal executive offices) (Zip Code) Registrant's telephone no., including area code: (650) 513-0990 -------------- NOT APPLICABLE - -------------------------------------------------------------------------------- (Former name or former address, if changed since last report) Item 5. Other Events. On November 6, 1998, DepoMed, Inc. issued a press release announcing that its common stock and warrants had been approved for listing on the American Stock Exchange. The press release is attached hereto as Exhibit 99.1. The Exhibit hereto is incorporated by reference herein and forms an integral part hereof. Item 7. Financial Statements and Exhibits. Exhibits. 99.1 Press Release dated November 6, 1998. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Date: November 9, 1998 DEPOMED, INC. /s/ John F. Hamilton ------------------------ John F. Hamilton Vice President - Finance and Chief Financial Officer EXHIBIT INDEX Exhibit 99.1 Press Release dated November 6, 1998. EX-99.1 2 PRESS RELEASE DATED NOVEMBER 6, 1998 EXHIBIT 99.1 DEPOMED, INC. LISTS ON THE AMERICAN STOCK EXCHANGE FOSTER CITY, Calif.--Nov. 6, 1998--DepoMed, Inc. (Nasdaq:DPMD) announced that its common stock and warrants (Nasdaq:DPMDW) have been approved for listing on the American Stock Exchange under the symbols "DMI" and "DMIW," respectively. The company expects trading to begin on Monday, Nov. 9. The company has selected Cohen Specialists L.L.C./PALBRO Partners L.L.C. as its specialist unit. "Our listing on the AMEX is an important milestone for DepoMed," commented John F. Hamilton, the company's chief financial officer. "The move to the AMEX is expected to increase corporate visibility, make trading more efficient and reduce trading costs for our shareholders." DepoMed, Inc., a development stage company, is engaged in the development of new and proprietary oral drug delivery technologies. The company has developed two types of proprietary oral drug delivery systems, the Gastric Retention System, designed to be retained in the stomach for an extended period of time while it delivers the incorporated drug or drugs, and the Reduced Irritation System, designed to reduce gastrointestinal irritation, a side effect of many orally administered drugs. Additional information may be found at the company's Web site at www.depomedinc.com. The statements in this press release that are not historical facts are forward- looking statements that involve risk and uncertainties, including risks identified in the company's registration statement on Form SB-2 (File No. 333- 25445), annual report on Form 10-KSB and other filings with the Securities and Exchange Commission. Actual results, events, and performance may differ materially. Readers are cautioned not to place undue relevance on these forward- looking statements, which speak only as of the date hereof. The company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statement contained herein to reflect any change in the company's expectations with regard thereto or any change in events, conditions or circumstances on which any statements are based. CONTACT: DepoMed John F. Hamilton, 650/513-0990 (VP & CFO) -----END PRIVACY-ENHANCED MESSAGE-----